CHUGAI PHARMACEUTICAL CO.,LTD.｜INNOVATION BEYOND IMAGINATION

News Releases
What's New

Apr 20: Corporate
Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
Apr 18: Product
Launch of the Anti-Cancer Agent / a Humanized Anti-PD-L1 Monoclonal Antibody “TECENTRIQ^®”
Apr 17: R&DProduct
Chugai’s HEMLIBRA® Receives Breakthrough Therapy Designation
from U.S. FDA for Hemophilia A without Factor VIII Inhibitors -The Sixth Designation for Chugai Originated Drug-
Apr 11: CorporateProduct
Waiver of Claims in Patent Infringement Lawsuit
Mar 28: CorporateProduct
Favorable Ruling in Patent Infringement Lawsuit Relating to Emicizumab

More

Apr 17: Events & Presentations has been updated with the Time of the Financial Results
Apr 13: Webcast of Information Meeting on TECENTRIQ^®
Apr 12: Information Meeting on TECENTRIQ®
Apr 02: Updated Directors & Officers
Mar 29: Events & Presentations has been updated with the date of the Financial Results

Share Price

TSE Code 4519

Share Graph

Video Introduction of CHUGAI

Videos & Advertisements

Back to top

Chugai Pharmaceutical Co., Ltd. takes great care over the information presented on this website, but it does not guarantee its accuracy, completeness, usefulness, etc. Furthermore, Chugai Pharmaceutical Co., Ltd. will not be responsible for any damages resulting from the use of this website or the information presented on this website. For further details, please read the following "Terms and Conditions of Website Use."

Share Price

Message from the CEO

R&D

Development
Pipeline

CSR

Recruit

Video Introduction of CHUGAI

Share Price

Message from the CEO

R&D

DevelopmentPipeline

CSR

Recruit

Video Introduction of CHUGAI

Development
Pipeline